Non-celiac gluten sensitivity (NCGS) is a resurfaced emerging disorder characterized by intestinal and extra-intestinal symptoms related to the ingestion of gluten-containing food in subjects not affected with either celiac disease (CD) or wheat allergy. Despite lacking solid epidemiological data, its prevalence has been estimated five to ten-times higher than that of CD and sells from gluten-free food market have rocketed three-fold lately. Unlike CD, NCGS seems to be associated with activation of the innate immune response. NCGS remains a diagnosis of exclusion of CD, due to the absence of diagnostic specific biomarkers. Evolving evidence has pointed the possibility of a relevant proportion of NGCS in literature actually suffering from overlooked minor forms of CD, the so-called "celiac lite" disease. The efficacy of a gluten-free diet for NCGS is controversial and other components in wheat, specially low-fermentable, poorlyabsorbed, short-chain carbohydrates have been lately postulated as major contributors to symptoms, instead of gluten. This review updates evidence on epidemiology, pathophysiology, diagnosis and dietary interventions in NCGS, stressing the need of thorough screening for CD before a diagnosis of NCGS is given, considering that natural history and dietary restriction for both entities are radically different.
Introduction
Non-celiac gluten sensitivity (NCGS) was originally described in 1976 and 1978 1, 2 and the first series dates back to 1980 3 , but only since 2010 a rapidly increasing number of papers have called our attention to an apparently novel syndrome entity, which has challenged physicians and researchers involved in gluten-related disorders. NCGS is characterized by intestinal and extraintestinal symptoms related to the ingestion of gluten-containing food, in subjects that are not affected with either celiac disease (CD) or wheat allergy. . A recent report revealed that about a third of U.S.
adults (the highest percentage ever) expressed their willingness of avoiding gluten from their diets 6 . Therefore, NCGS has definitely settled down among gluten related disorders as a clinical, social and economical relevant entity.
The proposed diagnostic criteria for NCGS are displayed in Table 1 7-9 , whereas the main pathogenic and clinical differences between CD and NCGS are summarized in Table 2 8
. The present review aims to critically overview available evidence on NCGS, focusing on epidemiology, adequate distinction of CD before a diagnosis of NCGS, pathogenesis and the efficacy of different dietary interventions for NCGS patients. 
Gluten-free diet (GFD)
A strict GFD modifies the natural history of the disease A strict GFD does not seem mandatory on account of its natural history * According to ESPGHAN updated guidelines 10 , CD antibodies are not detectable in the blood of all patients with CD; in seronegative cases for anti-TG2, EMA, and anti-DGP but with severe symptoms and a strong clinical suspicion of CD, small intestinal biopsies and HLA-DQ testing are recommended. According to Catassi and Fassano´s diagnostic rules 11 , response to a GFD supporting a diagnosis of CD could be assessed histologically in patients with seronegativity. ** According to ESPGHAN updated guidelines 10 , LE without villous atrophy might be specific for CD upon high count of  cells (or /CD3 ratio) in immunohistochemical assessment of biopsies or the presence of IgA anti-TG2 intestinal deposits. According to Catassi and Fassano´s diagnostic rules 11 , celiac enteropathy in the small intestine biopsy could be LE without villous atrophy associated with IgA subepithelial deposits.
Epidemiology
The overall prevalence of NCGS in the general population is still unknown, mainly because many patients are currently self-diagnosed and start a gluten-free diet (GFD) without medical advice or consultation. Besides, NCGS lacks diagnostic biomarkers. Despite no solid epidemiological study on NCGS is available, it has been reported to be five to ten times more common than CD 4, 9 . Recent studies have shown variable rates of self-reported NCGS (0.55% in the USA 12 , 5% in children in New Zealand 13 , 13% in adults in UK 14 ).
In patients with self-reported gluten sensitivity, gluten avoidance is associated with improvement of nonspecific behavioral and gastrointestinal complaints 13, 15 . However, the vast majority of the NCGS children involved in one of the aforementioned studies were not tested for CD nor underwent an intestinal biopsy 16 . In the study from the UK, 7% of patients were reclassified as having CD during the study 14 , whereas a more recent study conducted in Australia pointed out that just over 1 in 4 self-reporting improvement on a GFD fulfilled strict criteria for a diagnosis of NCGS 17 . Furthermore, initiation of a GFD without adequate exclusion of CD occurred in 62% of patients. As such, an inadequate exclusion of CD in patients with self-reported improvement on a GFD (not performing HLA genotyping and serology combined with small bowel biopsy if positive haplotypes), might lead to an overestimation of both the prevalence of NCGS and the response to a GFD in patients with NCGS.
Although risk factors for NCGS have not yet been identified, the disorder seems to be more common in females and in young/middle age adults. The prevalence of NCGS in children is still unknown, although the first series has been recently described 18 .
Clinical Picture and Natural History
NCGS is characterized by symptoms that usually occur soon after gluten ingestion, disappear with gluten withdrawal and relapse following gluten challenge, within hours or few days. The "classical" presentation of NCGS is a combination of irritable bowel syndrome-like symptoms, including abdominal pain, bloating, bowel habit abnormalities (either diarrhea or constipation), and systemic manifestations such as "foggy mind", headache, fatigue, joint and muscle pain, leg or arm numbness, dermatitis (eczema or skin rash), depression [7] [8] [9] . It is also quite common that many NCGS patients self-report the causal relationship between the ingestion of gluten-containing food and worsening of symptoms. In children, extra-intestinal manifestations seem to be less frequent, the most common symptom being tiredness 18 .
No familiar aggregation or major complication of untreated NCGS has so far been described, especially malabsorption-related and autoimmune comorbidities [7] [8] [9] . Interestingly, several studies have reported a remarkable prevalence of malabsorption symptoms, familiar history of CD and autoimmune disorders among NCGS patients 3, [19] [20] [21] [22] [23] [24] . Yet again, concerns arise about the possibility of having labelled CD patients as having NCGS. [7] [8] [9] . LE is a non-specific histological lesion which may be associated not only to CD, but also to Helicobacter pylori infection, small bowel bacterial overgrowth or use of anti-inflammatory drugs. However, the most frequent cause of LE in patients with positive HLA-DQ2/DQ8 after exhaustive diagnostic work-up has been CD, ranging from 16% to 43% [25] [26] [27] [28] .
NCGS: How Many
Furthermore, seronegative CD is more common in patients without villous atrophy, but Marsh 1 patients may have similar clinical manifestations than those with villous atrophy 29, 30 and may show similar clinical-histological remission and reversal of haematological or biochemical disturbances on a GFD 31, 32 .
As such, it would be important to make a clear distinction between CD Overall, evolving evidence is suggesting that a subset of patients with NCGS may actually belong to the spectrum of CD, specifically some patients with negative antibodies and without villous atrophy, which some authors have so-called "celiac lite" disease 34 .
There are two studies which might be prime example for this train of thought. In the first one, conducted in Germany, the authors thoroughly evaluated 102 patients with diarrhea-type IBS in whom CD had been precluded through negative serology and absence of villous atrophy 35 . Thirty five percent of patients were HLADQ2 positive, 23% had LE and notably, 30% had CD-associated antibodies in duodenal aspirate. Those HLADQ2 and intestinal antibody-positive IBS patients significantly improved on a GFD and were likely celiac patients. The second study, from Italy, showed 70 adult NCGS patients who were identified through a double-blind randomized placebo-controlled wheat trial 20 . All patients were seronegative and had no villous atrophy, but 94% NCGS patients had LE, 75% CD haplotypes and 30% positive anti-endomysium antibodies in the supernatant of biopsy culture 36 . The authors further admitted that these latter 30% of NCGS patients could actually suffer from CD 37 . Therefore, the inclusion of patients with positive HLA-DQ2/DQ8 and LE as having NCGS, in the absence of adequate efforts to exclude CD, will always cast doubt on potential misdiagnosis of "celiac lite" disease. In this respect, the importance of misdiagnosing NCGS in CD patients relies not only on the possibility of a CD patient following a non strict GFD, but also on overestimating response to a GFD in NCGS patients.
Pathogenesis
The pathophysiology of NCGS is not fully understood yet. Several pioneers studies suggested an important role of the intestinal innate immune system in NCGS, unlike CD, which is triggered by an adaptive immune response 38, 39 .
However, more recent studies have posed the possibility of NCGS being a mixed disease, with an activation of both innate and adaptative immunity 40, 41 .
Over the last 3 years, we have witnessed a progressive weakening of an unquestioned dogma, such as gluten-related proteins being the cause for NCGS. As a matter of fact, wheat has multiple constituents, so discussion of Several studies have addressed different hypothesis to explain symptom production after wheat ingestion in NCGS patients [44] [45] [46] [47] [48] [49] [50] , which are summarized in Table 3 . Table 3 . Putative pathogenic mechanisms to explain symptoms in NCGS patients after wheat ingestion.
Effects of gliadin in intestinal mucosa
• Increase of epithelial permeability with alteration in protein expression of components of the tight junction (zonulin) 44 • Activation of the innate immune response determined as IL-15 production (in vitro studies) and increased number of intraepithelial lymphocytes 45 • Induction of apoptosis, increase of oxidative stress and inhibition of epithelial cells growth (in vitro studies) 46 • Enhance of cytokine production by peripheral blood mononuclear cells, independent of DQ-status and induction of basophil activation (in vitro studies) 44 • Stimulation of cholinergic nervous system secondary to acetylcholine release by the myenteric plexus (animal studies) 47 
Fructans and undigested gluten proteins
• Carbohydrates present in wheat, such as fructans, are poorly absorbed and may produce gastrointestinal symptoms 48 • Fermentation of undigested gluten protein by sulphate-reducing bacteria can produce hydrogen sulphide and ammonia. Such gases might have a local effect of luminal distension and systemic effects (tiredness) 49 • Other gluten proteins, including alpha-amylase/trypsin inhibitors, and even yeast, could also play a role as triggers of the innate immune response ; however, in a second trial with a crossover design, there were no differences between, high-gluten, low-gluten or placebo challenge 52 . In the run-in period of this latter study, patients received a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) while maintaining the GFD. Noteworthy, patients whom had been included in the study due to symptom improvement on a GFD, showed a further significant clinical improvement on this run-in period 51 . Furthermore, high-gluten challenge did not worsen abdominal symptoms in a third trial, but NCGS patients showed high depression scores when compared to placebo, but interestingly not to high-whey 53 . In these three trials, CD was excluded on the basis of a HLA-DQ2 and DQ8 negative genetic study or a normal duodenal histology (Marsh 0) on patients HLA-DQ2/8 positive.
A recent study published in abstract form evaluating the efficacy of a GFD and afterwards a low FODMAP diet in patients given a diagnosis of NCGS 54 , disclosed that the proportion of NCGS patients responsive to carbohydrate restriction outnumbered that of patients responding to a GFD. Overall, evolving evidence suggests there might be different patients lumped together under the NCGS term: "celiac lite" patients, NCGS patients (an entity mediated through activation of the innate immunity) and patients intolerant to FODMAPs (carbohydrate intolerance).
Conclusions
NCGS is an emerging novel entity overlapping with CD and irritable bowel syndrome, lacking diagnostic criteria or biomarkers. This novel concept has been adopted by public far more readily than the medical scientific community (the ratio for the number of Google vs. PubMed citations for the terminology non-celiac gluten sensitivity was 4,598:1) 55 . In fact, epidemiology, diagnosis and the efficacy of a GFD are largely surrounded by controversy.
Concerns about labelling minor forms of CD disease as NCGS have lately arisen, since both diseases have radically different levels of dietary restriction and prognosis if untreated. We currently now that gluten withdrawal may definitely provide clinical benefit to a subset of non-celiac patients, but possibly fermentable carbohydrate (FODMAP) restriction during a GFD may play a major role in symptom improvement. Now, more than ever, we need to separate the wheat from the chaff regarding NCGS and upcoming research will probably shed more light on all of these questions 56 .
Epidemiology
• The overall prevalence of NCGS in the general population is still unknown, mainly due to lack of diagnostic markers, besides many patients are currently self-diagnosed and start a gluten-free diet (GFD) without medical advice or consultation.
• The growing market for gluten-free foods, which rocketed three-fold during the last 5 years, makes it even harder to decipher whether NCGS is a medical insight or a fad.
Natural History
• Unlike CD, no familiar aggregation, coexisting conditions (malabsorption and nutrition deficiencies, auto-immune disorders) and long-term complications have been described for NCGS.
• A diagnosis of NCGS in patients with gluten-dependent symptoms and familiar history of CD, malabsorption signs/symptoms or auto-immune diseases will always cast doubt on the possibility of these patients actually belonging to the spectrum of CD ("celiac-lite" disease).
• The importance of misdiagnosing NCGS in CD patients relies not only on the possibility of a CD patient following a non strict GFD, but also on overestimating response to a GFD in NCGS.
Diagnosis
• Gastrointestinal and extraintestinal symptoms in NCGS are indistinguishable from those present in CD.
• NCGS lacks diagnostic biomarkers, so it still remains a diagnosis of exclusion of CD
• Emerging evidence is pointing out inadequate exclusion of CD in a remarkable proportion of NCGS patients.
• Seronegativity and/or absence of villous atrophy may not positively rule out CD in patients with gluten-dependent symptoms
Pathogenesis
• Unlike CD, NCGS is mainly driven by activation of innate immunity
• Currently, gluten is not believed to be the only culprit component in wheat for NCGS
• Other wheat components, specially fructans as fermentable carbohydrates, have been postulated as a potential explanation for symptoms after wheat consumption. These pathogenic pathways do not activate innate immunity but have to do with carbohydrate colonic fermentation.
Therapy
• Currently, no solid evidence support a GFD for NCGS patients.
• Compared to a GFD, recent randomized double-blind trials have shown a higher efficacy of a low FODMAP diet for NCGS patients.
• On account of variable responses to different dietary intervention, emerging evidence is posing the possibility of different patients lumped together under the NCGS term: "celiac lite" patients, NCGS patients (an entity mediated through activation of the innate immunity) and patients intolerant to FODMAPs (carbohydrate intolerance).
